Propel Bio Management
$191M 13F equity value
41 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Propel Bio Management covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| PAGP | PLAINS GP HOLDINGS LP-CL | 1,272,360 | $31M | 16.2% |
| ACHV | ACHIEVE LIFE SCIENCES INC | 4,034,018 | $26M | 13.8% |
| CORT | CORCEPT THERAPEUTICS INC | 136,499 | $12M | 6.2% |
| PHAT | PHATHOM PHARMACEUTICALS I | 1,050,358 | $11M | 6.0% |
| DCTH | DELCATH SYSTEMS INC | 871,460 | $11M | 5.7% |
| MIST | MILESTONE PHARMACEUTICALS | 7,429,590 | $10M | 5.2% |
| CMPS | COMPASS PATHWAYS PLC | 573,086 | $8M | 4.2% |
| KYTX | KYVERNA THERAPEUTICS INC | 883,198 | $8M | 4.1% |
| ARTV | ARTIVA BIOTHERAPEUTICS IN | 696,436 | $7M | 3.5% |
| ABEO | ABEONA THERAPEUTICS INC | 983,070 | $6M | 3.2% |
Track Propel Bio Management's 13F portfolio: $191M in reported holdings, 41 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}